| Primary |
| Colon Cancer |
39.3% |
| Colorectal Cancer |
19.2% |
| Rectal Cancer |
11.4% |
| Colorectal Cancer Metastatic |
8.2% |
| Colon Cancer Metastatic |
2.9% |
| Drug Toxicity Prophylaxis |
2.5% |
| Gastrointestinal Stromal Tumour |
2.3% |
| Hypertension |
2.0% |
| Prophylaxis |
1.8% |
| Metastatic Colon Cancer |
1.4% |
| Neoplasm Malignant |
1.4% |
| Pain |
1.3% |
| Rectosigmoid Cancer |
1.3% |
| Colon Cancer Stage Iv |
1.0% |
| Product Used For Unknown Indication |
1.0% |
| Gastritis Prophylaxis |
0.8% |
| Metastases To Liver |
0.6% |
| Nausea |
0.6% |
| Rectal Cancer Metastatic |
0.6% |
| Constipation |
0.5% |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
14.2% |
| Vomiting |
9.0% |
| Stomatitis |
7.8% |
| Rash |
7.6% |
| Weight Decreased |
7.6% |
| Colorectal Cancer |
5.5% |
| Pyrexia |
5.5% |
| Rash Generalised |
4.9% |
| Skin Exfoliation |
4.7% |
| Fatigue |
4.1% |
| Drug Ineffective |
3.8% |
| Pain In Extremity |
3.8% |
| Colon Cancer |
3.2% |
| Death |
3.2% |
| Nausea |
2.9% |
| Off Label Use |
2.6% |
| White Blood Cell Count Decreased |
2.6% |
| Diarrhoea |
2.3% |
| Liver Function Test Abnormal |
2.3% |
| Pneumonia |
2.3% |
|
| Secondary |
| Colon Cancer |
43.3% |
| Colorectal Cancer |
13.4% |
| Rectal Cancer |
12.7% |
| Colorectal Cancer Metastatic |
6.3% |
| Drug Toxicity Prophylaxis |
3.5% |
| Prophylaxis |
3.1% |
| Rectosigmoid Cancer |
2.1% |
| Colon Cancer Metastatic |
2.0% |
| Hypertension |
1.7% |
| Colon Cancer Stage Iv |
1.6% |
| Gastric Cancer |
1.6% |
| Gastritis Prophylaxis |
1.6% |
| Gastrointestinal Stromal Tumour |
1.5% |
| Metastatic Colon Cancer |
1.3% |
| Polyuria |
1.1% |
| Metastases To Liver |
0.9% |
| Adverse Event |
0.5% |
| Anticoagulant Therapy |
0.5% |
| Blood Cholesterol Abnormal |
0.5% |
| Blood Pressure Abnormal |
0.5% |
|
| Weight Decreased |
13.5% |
| Vomiting |
12.2% |
| Stomatitis |
10.9% |
| Skin Exfoliation |
6.4% |
| Pain In Extremity |
5.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
5.8% |
| Nausea |
4.5% |
| Rash |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Rash Generalised |
3.8% |
| Tremor |
3.8% |
| Tumour Marker Increased |
3.8% |
| Vision Blurred |
3.8% |
| Pyrexia |
3.2% |
| Rectal Cancer |
2.6% |
| Stoma Site Haemorrhage |
2.6% |
| Urinary Retention |
2.6% |
| Chest Pain |
1.9% |
| Gynaecomastia |
1.9% |
| Hypertensive Crisis |
1.9% |
|
| Concomitant |
| Rectal Cancer |
60.0% |
| Colon Cancer |
20.0% |
| Product Used For Unknown Indication |
20.0% |
|
| Drug Ineffective |
33.3% |
| Rash Generalised |
33.3% |
| Skin Ulcer |
33.3% |
|
| Interacting |
|
|
